Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2014 by Omeros Corporation
Sponsor:
Information provided by (Responsible Party):
Omeros Corporation
ClinicalTrials.gov Identifier:
NCT02074410
First received: February 21, 2014
Last updated: September 10, 2014
Last verified: September 2014

February 21, 2014
September 10, 2014
January 2014
March 2015   (final data collection date for primary outcome measure)
  • Assess the Safety of OMS643762 [ Time Frame: 28 days ] [ Designated as safety issue: Yes ]
    Safety as assessed by adverse events
  • Assess the Safety of OMS643762 [ Time Frame: 28 days ] [ Designated as safety issue: Yes ]
    Safety as assessed by vital signs
  • Assess the Safety of OMS643762 [ Time Frame: 28 days ] [ Designated as safety issue: Yes ]
    Safety as assessed by clinical lab-tests
  • Assess the Safety of OMS643762 [ Time Frame: 28 days ] [ Designated as safety issue: Yes ]
    Safety as assessed by ECG
  • Assess the Safety of OMS643762 [ Time Frame: 28 days ] [ Designated as safety issue: Yes ]
    Safety as assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)
Same as current
Complete list of historical versions of study NCT02074410 on ClinicalTrials.gov Archive Site
  • Motor function [ Time Frame: Pre-dose and day 15 and 28 post-dose ] [ Designated as safety issue: No ]
    Change from baseline in the UHDRS - Total Motor Score
  • Motor function [ Time Frame: Pre-dose and day 15 and 28 post-dose ] [ Designated as safety issue: No ]
    Change from baseline in the Speeded Tapping Test score
  • Cognition [ Time Frame: Pre-dose and day 28 post-dose ] [ Designated as safety issue: No ]
    Change from baseline in the Cognitive Assessment Battery composite score
  • Behavior [ Time Frame: Pre-dose and day 28 of dosing ] [ Designated as safety issue: No ]
    Change from baseline in the Problem Behavior Assessment score
  • Pharmacokinetics [ Time Frame: Pre-dose, day 15 and 28 of dosing and up to 14 days post-dose ] [ Designated as safety issue: No ]
    Maximum plasma concentration of OMS643762 following multiple-dose administration
Same as current
Not Provided
Not Provided
 
Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease
Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease

The purpose of this study is to determine the safety, tolerability and pharmacokinetics of OMS643762 (the study drug) in subjects with Huntington's disease (HD).

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Huntington's Disease
  • Drug: OMS643762
    Other Name: OMS824
  • Drug: Placebo
  • Experimental: OMS643762 Low Dose without food
    Orally administering OMS643762 low dose daily without food for 28 days
    Intervention: Drug: OMS643762
  • Experimental: OMS643762 Medium Dose without food
    Orally administering OMS643762 medium dose daily without food for 28 days
    Intervention: Drug: OMS643762
  • Experimental: OMS643762 Medium Dose with food
    Orally administering OMS643762 Medium dose daily with food for 28 days
    Intervention: Drug: OMS643762
  • Placebo Comparator: Placebo
    Orally administering placebo daily for 28 days
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
36
March 2015
March 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Voluntarily provide informed consent, or have a legally authorized representative (LAR) provide informed consent with subject assent, in accordance with local regulations and governing Institution Review Board (IRB) requirements prior to any procedures or evaluations performed specifically for the sole purpose of the study (other than the Montreal Cognitive Assessment (MoCA) to assess capacity to provide informed consent). Capacity to provide informed consent will be determined by the MoCA and investigator judgment according to the following:

    • Subjects with scores of greater than or equal to 21 on the MoCA and, in the judgment of the investigator, have the capacity to provide valid informed consent, can give consent.
    • Subjects with scores of less than 21 but greater than or equal to 18 on the MoCA and, in the judgment of a mental health professional (independent of the investigator) have the capacity to provide valid informed consent, may give consent.
    • Subjects with scores less 21 but greater than or equal to 18 on the MoCA, who lack the capacity to give valid informed consent, in the judgment of a mental health professional (independent of the investigator), will need an LAR to provide informed consent with assent by the subject.
    • Subjects with scores of less than 18 on the MoCA will have an LAR provide informed consent with assent by the subject.
  2. Have a clinical diagnosis of HD, confirmed by either CAG repeat number of greater than or equal to 39 or a positive family history (a first degree relative with a clinical diagnosis of HD) if CAG repeat number is not known.
  3. Are age greater than or equal to 18 and less than or equal to 65 years at the screening visit (Visit 1).
  4. Have a UHDRS Total Functional Capacity greater than or equal to 7 at Visit 1.
  5. If currently taking antipsychotic medication(s), have been on a stable regimen for at least 60 days prior to randomization.
  6. Are fluent in English.
  7. If female, are either a) not of childbearing potential (i.e., surgically sterilized or post-menopausal for more than 1 year) or b) have a negative pregnancy test and if sexually active must agree to use a medically reliable form of contraception throughout the study. Acceptable methods of contraception include a reliable intrauterine device, hormonal contraception or spermicide in combination with a barrier method.
  8. If male, are either a) not of reproductive potential or b) if sexually active must agree to use a medically reliable form of contraception throughout the study. Acceptable methods of birth control include spermicide in combination with a barrier method, or subjects' female partner is willing to use medically acceptable methods of birth control.
  9. Have normal clinical laboratory test results and ECG, or results with minor deviations, which are not considered to be clinically significant by the investigator.

Exclusion Criteria:

  1. Have a history or presence of significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, or neurological disorders other than HD which, in the opinion of the investigator, increases the risk of the study drug or may confound the interpretation of study measures.
  2. Have unstable or severe depression, in the opinion of the investigator.
  3. Have alcohol or drug abuse or dependence, as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision.
  4. Have received treatment with an investigational drug or device within 60 days prior to Visit 1.
  5. Are pregnant or lactating.
  6. Have serum alanine transaminase or aspartate transaminase greater than two times upper limit of normal at screening.
  7. Have hemoglobin, white blood cell count, absolute neutrophil count, or platelet count outside the normal range at screening.
  8. Are an employee of Omeros, an investigator, or study staff member, or their immediate family member.
Both
18 Years to 65 Years
No
Contact: Lisa Kelbon 206-676-5000 lkelbon@omeros.com
United States
 
NCT02074410
OMS824-HTD-002
No
Omeros Corporation
Omeros Corporation
Not Provided
Study Director: Steve Whitaker, MD Omeros Corporation
Omeros Corporation
September 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP